Teva Pharmaceutical Industries has launched AHZANTIVE® (aflibercept), a biosimilar referencing Regeneron and Bayer's Eylea® (aflibercept), across European markets, marking a significant addition to the company's expanding biosimilars portfolio and its deepening footprint in ophthalmology. The Tel Aviv-based pharmaceutical manufacturer announced the move on June 4, 2026, framing it as a strategic step toward broadening patient access to biologic medicines in areas of high clinical need.
Aflibercept is a recombinant fusion protein that functions as a vascular endothelial growth factor (VEGF) trap, binding VEGF-A and placental growth factor to inhibit neovascularization — the mechanism underlying retinal conditions such as wet age-related macular degeneration (AMD) and diabetic macular edema. Biosimilar development for complex biologics of this class requires demonstrating analytical, functional, and clinical comparability to the reference product under rigorous regulatory review by the European Medicines Agency (EMA), a process that parallels FDA biosimilar pathway standards under 351(k) of the Public Health Service Act.
The biosimilars category has drawn sustained investment as reference biologic patents mature and health systems seek cost-containment options without sacrificing therapeutic equivalence. European payers have been particularly receptive to biosimilar substitution policies, and ophthalmology indications — where anti-VEGF injections represent a significant share of hospital pharmacy spend — present a compelling volume opportunity for manufacturers with credible supply chain infrastructure. Teva has positioned its biosimilars business as a growth engine distinct from its generics heritage, citing strong partnerships and commercial capabilities as competitive differentiators.
For operators in the nutraceutical and functional food space monitoring adjacent ingredient and delivery innovation — particularly those working with bioavailability-enhancing technologies or ocular health formulations — the continued maturation of the biosimilar sector signals broader regulatory and scientific momentum around evidence-based, mechanism-driven health products. Ingredient suppliers developing structure-function claim dossiers for lutein, zeaxanthin, or omega-3 finished formulations targeting eye health may find the clinical endpoint frameworks established in biologic ophthalmology useful reference points. Industry observers tracking regulatory developments across biologics and dietary supplements note that evidentiary standards are converging across categories as the FDA and EMA align on benefit-risk documentation.
Teva did not disclose European launch pricing or volume projections in its announcement. The company is publicly traded on both the NYSE and Tel Aviv Stock Exchange under the ticker TEVA. This release was sourced via Food & Beverage Magazine partner network monitoring.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.